Cargando…

Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade

BACKGROUND: Although the second-generation androgen receptor inhibitors and taxanes have recently been recommended for the initial treatment of metastatic prostate cancer, bicalutamide and flutamide are still used in a large number of cases. Therefore, it is important to elucidate the clinical chara...

Descripción completa

Detalles Bibliográficos
Autores principales:	Obinata, Daisuke, Hashimoto, Sho, Uchida, Hideaki, Nakahara, Ken, Yoshizawa, Tsuyoshi, Mochida, Junichi, Yamaguchi, Kenya, Takahashi, Satoru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148407/ https://www.ncbi.nlm.nih.gov/pubmed/37118708 http://dx.doi.org/10.1186/s12894-023-01233-6

Ejemplares similares

Initial experience with prostatic urethral lift versus enucleation of the prostate: a retrospective comparative study
por: Obinata, Daisuke, et al.
Publicado: (2023)

Characteristics of prostate biopsy in patients under the dutasteride treatment
por: Obinata, Daisuke, et al.
Publicado: (2022)

Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer
por: Uchida, Hideaki, et al.
Publicado: (2023)

An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy
por: Yoshizawa, Tsuyoshi, et al.
Publicado: (2019)

Rezūm water vapor thermal therapy in patients with benign prostatic hyperplasia: Initial real-world data from Japan
por: Obinata, Daisuke, et al.
Publicado: (2023)

Tension-free vaginal mesh for patients with pelvic organ prolapse: mid-term functional outcomes
por: Obinata, Daisuke, et al.
Publicado: (2022)

Real-world efficacy of sequential nivolumab for metastatic renal cancer after first-line molecular targeting therapy
por: Obinata, Daisuke, et al.
Publicado: (2022)

Low reduction of prostate volume is a significant predictor of prostate cancer at subsequent biopsy in patients with dutasteride: A retrospective study
por: Obinata, Daisuke, et al.
Publicado: (2020)

Case of caval lobular capillary hemangioma mimicking tumor thrombus
por: Hashimoto, Sho, et al.
Publicado: (2019)

Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2017)

Successful lymphatic embolization using N-butyl-2-cyanoacrylate for postoperative lymphorrhea in a patient with renal pelvic cancer
por: Irie, Yuki, et al.
Publicado: (2020)

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2020)

CLDN8, an androgen‐regulated gene, promotes prostate cancer cell proliferation and migration
por: Ashikari, Daisaku, et al.
Publicado: (2017)

Identification of new octamer transcription factor 1‐target genes upregulated in castration‐resistant prostate cancer
por: Yamamoto, Shinichiro, et al.
Publicado: (2019)

Predicting castration-resistant prostate cancer after combined androgen blockade
por: He, Miao, et al.
Publicado: (2017)

Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer
por: Han, G. Celine, et al.
Publicado: (2017)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine
por: Fujimura, Tetsuya, et al.
Publicado: (2018)

Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer
por: Tamada, Satoshi, et al.
Publicado: (2018)

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
por: Nagai, Takashi, et al.
Publicado: (2018)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

A Case of IgA Vasculitis During Nivolumab Therapy for Renal Cell Carcinoma
por: Nagaoka-Takatori, Asami, et al.
Publicado: (2021)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
por: Li, Jian-Ri, et al.
Publicado: (2017)

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
por: Lavaud, Pernelle, et al.
Publicado: (2020)

Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
por: Marshall, Catherine H., et al.
Publicado: (2021)

Urethral injection of dedifferentiated fat cells ameliorates sphincter damage and voiding dysfunction in a rat model of persistence stress urinary incontinence
por: Murata, Yasutaka, et al.
Publicado: (2022)

Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review
por: Lukka, H., et al.
Publicado: (2006)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
por: Yamada, Shigetomo, et al.
Publicado: (2022)

An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
por: Tsuchiya, Tomohiro, et al.
Publicado: (2019)

Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Jang, Ho Seong, et al.
Publicado: (2016)

Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Ryan, Charles J, et al.
Publicado: (2019)

Complete androgen blockade vs. medical castration alone as adjuvant androgen deprivation therapy for prostate cancer patients following radical prostatectomy: a retrospective cohort study
por: Jin, Di, et al.
Publicado: (2022)

THU544 Prostatic Acid Phosphatase Is Negatively Regulated By Androgens And Persists In Castrate-resistant Metastatic Prostate Cancer
por: Rajagopalan, Vinodh, et al.
Publicado: (2023)

A marrow-minded look at immune checkpoint blockade resistance in metastatic castration resistant prostate cancer
por: Fonseca, Nicolette M., et al.
Publicado: (2021)

Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
por: Sugimoto, Mikio, et al.
Publicado: (2022)

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
por: Min, Kyungchan, et al.
Publicado: (2020)

Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance?
por: Niklas, Christina, et al.
Publicado: (2021)

Urinary exosome-based androgen receptor-variant 7 detection in metastatic castration-resistant prostate cancer patients
por: Wang, Chao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5o0jea2ghk09hitrv8hn5cfi5r